Cyclooxygenase (COX)-derived prostaglandins stimulate uterine contractions and prepare the cervix for parturition. Prior reports suggest Cox-1 knockout (KO) mice exhibit delayed parturition due to impaired luteolysis, yet the mechanism for late-onset delivery remains unclear. Here, we examined key factors for normal onset of parturition to determine whether any could account for the delayed parturition phenotype. Pregnant Cox-1KO mice did not display altered timing of embryo implantation or postimplantation growth. Although messenger RNAs of contraction-associated proteins (CAPs) were differentially expressed between Cox-1KO and wild-type (WT) myometrium, there were no differences in CAP agonist-induced intracellular calcium release, spontaneous or oxytocin (OT)-induced ex vivo uterine contractility, or in vivo uterine contractile pressure. Delayed parturition in Cox-1KO mice persisted despite exogenous OT treatment. Progesterone (P 4 ) withdrawal, by ovariectomy or administration of the P 4 -antagonist RU486, diminished the delayed parturition phenotype of Cox-1KO mice. Because antepartum P 4 levels do not decline in Cox-1KO females, P 4 -treated WT mice were examined for the effect of this hormone on in vivo uterine contractility and ex vivo cervical dilation. P 4 -treated WT mice had delayed parturition but normal uterine contractility. Cervical distensibility was decreased in Cox-1KO mice on the day of expected delivery and reduced in WT mice with long-term P 4 treatment. Collectively, these findings show that delayed parturition in Cox-1KO mice is the result of impaired luteolysis and cervical dilation, despite the presence of strong uterine contractions. (Endocrinology 159: 490-505, 2018) P regnancy duration and the onset of birth (parturition) are tightly regulated events (1-3). One of the early factors known to influence the timing of labor is the timing of embryo implantation. Delayed or poor embryo implantation can result in mistiming of parturition, in part due to delayed or poor in utero embryonic development and maturation (4-6). Multiple-gestation pregnancies also contribute to the timing of parturition: Larger numbers of offspring prompt an earlier delivery, whereas few offspring in polytocous species are associated with prolonged gestation (7, 8) . A larger-than-normal number of offspring triggers early-onset parturition due to premature stretch of uterine myometrial cells, activating the uterus to contract. The fetus and placenta also emit molecular signals that control the length of pregnancy and trigger the onset of labor (1, 9-11).
P regnancy duration and the onset of birth (parturition) are tightly regulated events (1) (2) (3) . One of the early factors known to influence the timing of labor is the timing of embryo implantation. Delayed or poor embryo implantation can result in mistiming of parturition, in part due to delayed or poor in utero embryonic development and maturation (4) (5) (6) . Multiple-gestation pregnancies also contribute to the timing of parturition: Larger numbers of offspring prompt an earlier delivery, whereas few offspring in polytocous species are associated with prolonged gestation (7, 8) . A larger-than-normal number of offspring triggers early-onset parturition due to premature stretch of uterine myometrial cells, activating the uterus to contract. The fetus and placenta also emit molecular signals that control the length of pregnancy and trigger the onset of labor (1, (9) (10) (11) .
In addition to fetal effects on the timing of partition, the two major maternal systems that effectuate labor include uterine myometrial contractions and cervical ripening and dilation. The uterus remains relatively quiescent throughout most of pregnancy. Transformation of the myometrium from its relaxed to active state is regulated by progesterone (P 4 ) withdrawal. In most mammals, this is achieved by declining circulating P 4 levels; in humans, this is accomplished by either a shift in P 4 receptor isoforms, changes in coactivator expression, increased steroid metabolism, or other mechanisms (12) (13) (14) (15) (16) (17) . Uterine activation enhances myometrial sensitivity to contractile stimuli, such as oxytocin (OT) and prostaglandins (PGs), and facilitates coordinated uterine contractions. This occurs through changes in myometrial contractionassociated proteins (CAPs), an increase in intracellular calcium release by myometrial smooth-muscle cells, and increased connectivity between these cells via gap-junction complexes, culminating in increased uterine contractile activity (13, (18) (19) (20) (21) (22) . The onset of rhythmic uterine contractions must be accompanied by cervical maturation (ripening and dilation) to allow delivery of the fetus. Inadequate uterine contractions or impaired cervical maturation results in unsuccessful (or dysfunctional) parturition (23) .
Genetically modified mouse models have enhanced our understanding of the complex interactions controlling the timing of parturition. To date, there are 14 known mouse models that exhibit delayed parturition by at least 24 hours (6, (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) . Several of these models are due to genetic disruptions in the PG biosynthesis pathway. PGs are essential mediators of pregnancy, with key roles in embryo implantation, luteolysis, and parturition. PGs are lipid mediators derived from the hydrolysis of cellular phospholipids. Arachidonic acid is converted into prostaglandin H2 by the two PG G/H synthases, prostaglandin-endoperoxide synthase 1 and 2 [Ptgs1 and Ptgs2; commonly referred to as cyclooxygenase 1 and 2 (Cox-1 and Cox-2)]. Historically, Cox-1 is considered the constitutive isoform, and Cox-2 is the inducible isoform. However, this may be an oversimplification, given that both Cox isoforms are upregulated in various physiological and pathological conditions (42) , and constitutive Cox-1 expression has been documented. Gene knockout (KO) and knockin studies in mice have shown the distinct, noninterchangeable functions of Cox-1 and Cox-2 (43, 44) . In the pregnant mouse uterus, Cox-1 expression is regulated by estrogen and P 4 (45) (46) (47) and increases with advancing gestation (48) . Mice lacking the Cox-1 gene (Cox-1KO) are a valuable model for studying parturition because of their delayed parturition phenotype (25, 29, 31) . In contrast, Cox-2 is rapidly induced in response to various cellular stimuli and is critical for ovulation, fertilization, and embryo implantation (49) (50) (51) . Studies on parturition in Cox-2-deficient mice are precluded by their early infertility phenotype (49) (50) (51) . Moreover, the nonpregnancy phenotypes of Cox-2KO mice are much greater than that of Cox-1KO mice, despite the role of Cox-1 in various housekeeping functions (43) . Specifically, Cox-1KO mice lack the expected gastric and kidney pathologies but exhibit reduced platelet aggregation (25) , decreased inflammatory response to arachidonic acid (25) , and other phenotypes (52) , in addition to delayed parturition (25, 29, 31) .
We previously showed that mice lacking cytosolic phospholipase A2, the critical upstream enzyme for PG synthesis, exhibit delayed parturition due to a delay in embryo implantation timing (6) . Studies using Cox-1KO female mice on a 129/Bl6 genetic background have reported their delayed-parturition phenotype as a consequence of impaired luteolysis. Specifically, these mice almost completely lack PGF 2a production (29, 31) , which normally acts on the corpus luteum of the ovary to induce luteolysis and cause the expected decline in plasma P 4 levels. Although OT-KO mice have decreased plasma P 4 levels, these mice do not display delayed parturition, because of their normal uterine PGF 2a levels (29) . Because mice lacking both OT and Cox-1 display normal timing of parturition and intact luteolysis in absence of elevated PGF 2a production (29) , the effects of OT and PG deficiency on uterine contractions and the parturition process are not fully understood.
In this study, we used Cox-1KO mice on an outbred CD-1 background to test our hypotheses that delayed parturition in these mice is due to either aberrant embryo implantation and/or ineffective labor caused by impaired myometrial contractility, in addition to their impaired luteolysis. The effects of Cox-1 deficiency on the cervix were considered as an alternative hypothesis. Thus, the aims of the study were to identify the contribution of endocrine, uterine, or cervical parameters to delayed parturition in Cox-1KO mice.
Materials and Methods

Materials
All chemicals were purchased from Millipore Sigma unless otherwise noted.
(31) were housed under a 12 hours of light:12 hours of dark cycle, with free access to food and water. Homozygous timed pregnancies were performed, and the presence of a copulatory plug was considered day 1 of pregnancy. Female WT and Cox-1KO mice were euthanized by exposure to isoflurane and then cervical dislocation on days 5, 6, 15, and 19 of pregnancy. Tissues from Cox-1KO mice were also collected on day 20 of pregnancy, given their delayed parturition phenotype. For each experiment, time-point data were obtained from 5 to 10 independent animals. For ovariectomy-induced parturition studies, Cox-1KO mice were either bilaterally ovariectomized or sham operated (control mice) on day 19, given the elevated P 4 levels in Cox-1KO mice on this day. The timing of delivery (intrapartum) was determined by continuous video recording of pregnant females, as previously described (6) , and defined as the complete delivery of the first pup. The number of offspring born alive at birth, stillborn, or died postnatally was recorded.
Timing of embryo implantation
Chicago Blue Dye (1% solution in saline) was injected into the tail vein of pregnant mice before euthanasia on the morning (8:00 AM) of day 5 and 6 of pregnancy, to visualize sites of embryo implantation (53, 54) . The total number of implantation sites was recorded, as were the weights of the intact uterus and individual implantation sites. Implantation sites were placed in 10% formalin-buffered saline, followed by routine histological processing and paraffin embedding. Paraffinembedded uterine cross-sections (5 mm) were stained with Mayer hematoxylin and eosin using standard methodology. Microscopic analysis was performed and photomicrographs of uterine sections containing embryos were taken using a camera-equipped Leica microscope (DF-450C and DMIL-LED, respectively).
Quantitative real-time polymerase chain reaction analysis
Quantitative real-time reverse transcription polymerase chain reaction analysis was performed as previously described (55) . Briefly, DNase-treated total RNAs (1 mg) were reversetranscribed using oligo(dT) primers according to the manufacturer's instructions (Invitrogen). One microliter of the first strand was amplified in 25 mL of total volume in an iCycler (BioRad Laboratories) using iQ SYBER Green Supermix (Bio-Rad). The following polymerase chain reaction protocol was used: 95°C for 3 minutes followed by 40 
Uterine myometrial prostaglandin measurements
Levels of PGF 2a , 6-keto-PGF 1a , PGD 2 , PGE 2 , and thromboxane B 2 were quantitatively determined by gas chromatographic/ negative ion chemical ionization mass spectrometric assays performed by the Vanderbilt University Eicosinoid Core Laboratory. Lipid extraction from uterine myometrial tissue and gas chromatographic/negative ion chemical ionization mass spectrometric assay were performed using exact methods as previously described (6) .
Isolation of uterine myometrial cells and intracellular calcium-release assay
Uterine myometrial cells were isolated and selectively enriched for myocytes using methods previously described (58) . Myometrial cells in complete media (40, 
Ex vivo assessment of uterine contractile function
Longitudinal strips (4 mm 3 12 mm) of uterine myometrium were prepared and used in an isometric contractility assay, as previously described (58) . Briefly, uterine strips were submersed in a heated and oxygenated (37°C; 95% O 2 and 5% CO 2 ) Radnoti tissue bath containing Kreb bicarbonate solution. Each strip was placed under 1 g of tension and allowed to equilibrate in the organ chamber for 60 minutes before recording baseline spontaneous contractile activity. After spontaneous contractions, cumulative doses of OT (10 pM to 1 mM) or PGF 2a (10 pM to 10 mM) were added to individual organ baths every 10 minutes. Isometric contractions were recorded using PowerLab/8SP hardware and analyzed with LabChart 7Pro software (ADInstruments). Contractile activity was assessed by mean amplitude, frequency, or area under the curve (AUC) relative to baseline divided by period assessed, which was ;600 seconds for spontaneous and treatment data. All treatment data were expressed as a percentage of the baseline spontaneous contractile activity.
In vivo assessment of uterine contractile function
On antepartum days 19 and 20 (Cox-1KO mice only) and intrapartum, WT and Cox-1KO female mice were anesthetized with 1.25% 2,2,2-tribromoethanol and placed on a heating pad. A speculum tube (0.5 cm wide 3 1.5 cm long) was inserted into the vaginal canal to visualize the cervix. A MikroTip ® pressure catheter (3.5F; Millar Instruments, ADInstruments) was inserted transcervically to a depth of 4 to 6 cm, which was a predetermined length to pass the pressure catheter beyond the uterocervical junction. After intrauterine contractions became rhythmic with similar amplitude and frequency, baseline intrauterine contractile pressure was recorded (measured in millimeters of mercury) with PowerLab 8/35SP and PCU-2000 (ADInstruments) hardware. Contractile pressure was evaluated with LabChart 7 Pro software (ADInstruments) in a way similar to that described for ex vivo contractile activity in the previous paragraph. Recordings of intrauterine pressure (IUP) were analyzed for integral of IUP above baseline over time (i.e., AUC), frequency, amplitude, and duration during 10 minutes.
Exogenous administration of OT, RU486, and P 4
OT was delivered at a constant rate via miniosmotic pumps (Alzet), as previously described (59) . OT was diluted in saline to the desired concentration. Miniosmotic pumps were loaded to deliver OT at two pumping rates, 0.5 mU/h (low dose) and 5 mU/h (high dose), and placed under the nuchal skin of mice on day 19 of pregnancy (4:00 PM) and continued through parturition. Similarly, control animals received miniosmotic pumps filled with saline.
The P 4 receptor antagonist RU486 was dissolved in 100% ethyl alcohol, diluted in sesame oil, and injected subcutaneously (0.03 mg or 0.3 mg per mouse) at 4:00 PM on day 19 of pregnancy, given that P 4 levels remain elevated on day 19 in Cox-1KO mice and that RU486 induces delivery within 24 hours in WT mice. Similarly, control animals received vehicle (100% ethyl alcohol diluted in sesame oil). P 4 was dissolved in sesame oil and injected subcutaneously (1 or 2 mg per mouse) daily at 9:00 AM on days 18 to 21 of pregnancy (60) (61) (62) .
Ex vivo testing of cervical dilation
Cervical tissues were excised as an intact cylindrical bloc by cutting along the uterocervical junction and removing the vaginal tissue. Whole cervical tissues (;5 mm) were mounted on two triangle-shaped metal hooks connected to a Radnoti force transducer at one end and the other connected to a glass rod submersed in a heated and oxygenated (37°C, 95% O 2 and 5% CO 2 ) Radnoti tissue bath containing Kreb bicarbonate solution. After a 10-minute equilibration period, the hooks were slowly distracted apart until the force transducer indicated measurable cervical tension, after which the separation between the hooks was reduced to determine the baseline dilation of the cervix tissue without strain-induced stress. Next, a stress-relaxation tissue-displacement protocol was performed in which the cervical tissue experienced a strain of 0.1 mm/s for a total of 10 seconds (1-mm displacement), after which the strain was held constant for 4 minutes. This cycle was repeated until tissue failure and was controlled using stepper motors (Applied Motion Products) connected to the force transducer. Total dilation was recorded as the baseline dilation plus the displacement during biomechanical testing before tissue failure.
Statistical analyses
GraphPad Prism 6.0e software (GraphPad Software) was used to plot results and perform statistical analyses. A two-way analysis of variance (ANOVA) was used to determine the effects of gestational day and genotype, followed by a separate, independent Student t test when comparing for a single day of pregnancy or Bonferroni correction when comparing day 19 WT mice and days 19 and 20 Cox-1KO mice. Dose-response curves were analyzed using four-parameter log fit to determine whether one curve fit all the data sets using extra sum-of-squares F test, as well as to determine whether the half maximal effective concentration (EC 50 ) values differ between data sets.
Comparisons of exogenous treatment on timing of delivery and fetal outcome were analyzed by a one-way ANOVA, followed by post hoc Bonferroni multiple comparison test. A two-way ANOVA was used to determine the effects of gestational day and treatment group, followed by separate post hoc Bonferroni multiple comparison test. Comparisons of delivery outcome in P 4 -treated and vehicle-treated WT mice were analyzed by x 2 test. P # 0.05 was considered statistically significant.
Results
Evaluation of embryonic implantation, postimplantation growth
Increasing evidence supports that defects in the embryo implantation process lead to adverse consequences on later gestational events, including placentation, embryonic growth, and parturition (4, 6, 33) . Therefore, we compared the timing of implantation and postimplantation pregnancy events between pregnant Cox-1KO and WT mice to determine whether the delayed parturition phenotype was a consequence of defects in early pregnancy. The pattern and spacing of distinct blue bands, indicative of normal sites of embryonic implantation, were similar in Cox-1KO and WT uteri on day 5 of pregnancy ( Fig. 1A) . Moreover, the number [mean 6 standard error of the mean (SEM)] of implantation sites present in Cox-1KO (13 6 0.63 per mouse) and WT pregnant females (13 6 0.71/mouse; Fig. 1B , left panel) did not differ. After careful dissection, the weight of implantation sites on days 5 or 6 of pregnancy did not differ between Cox-1KO and WT mice (Fig. 1B, right panel) . Histological analysis of implantation sites on days 5 and 6 of pregnancy showed no difference in the morphology of embryos or implantation sites (Fig. 1C) , including primary decidua formation in the antimesometrial region of the uterus, which forms a tight barrier around the embryo before the onset of placentation (63) (64) (65) .
Fetal size likely contributes to the onset of parturition; therefore, we compared the postimplantation fetal growth of Cox-1KO and WT female mice on days 15, 19, and 20 (Cox-1KO mice only) of pregnancy. There were essentially no differences noted between Cox-1KO and WT mice in the weight of intact utero-fetal-placental segments in early or midpregnancy ( Fig. 2A) other than a small but significant (P = 0.02) difference on day 19 of pregnancy. No differences were observed between individual uterine, placental, or fetal weights (Fig. 2B ) from Cox-1KO and WT mice on days 15 and 19 of pregnancy. Not surprisingly, Cox-1KO fetuses weighed significantly more (P , 0.0001) on day 20 than Cox-1KO and WT fetuses on day 19 of pregnancy, corresponding with continued in utero growth with prolonged gestation. By comparison, placental weights were diminished (P , 0.05) in Cox-1KO mice on day 20 (Fig. 2B) , which may reflect postmature placental aging during prolonged pregnancy (66, 67) . Taken together, these data indicate that embryo implantation and subsequent intrauterine fetal growth are not affected by the absence of Cox-1-derived prostaglandins during pregnancy.
Assessment of in vitro uterine contractile activity
An increase in intracellular calcium levels is the final common pathway controlling uterine myometrial contractions for labor (68) (69) (70) (71) . OT and PGs (i.e., PGF 2a and PGE 2 ) are potent endogenous contractile agonists (72, 73) that are used clinically for labor induction. To evaluate the uterine contractile potential of Cox-1KO mice, we began by examining myometrial messenger RNA (mRNA) expression of the OT and PGF 2a receptors (OR and Ptgfr, respectively), as well as the CAPs gap junction protein a 1 (Gja1, more commonly known as connexin 43 and, hereafter, Cx43), Cox-2 (Ptgs2) and endothelin-1 (1) (Fig. 3) .
For most CAPs examined on day 15 of pregnancy, there was no difference in expression between Cox-1KO and WT myometrium, except Ptgfr (P = 0.02). On day 19 of pregnancy, levels of Oxtr and Cx43 were significantly reduced (P , 0.03), but similar levels were present on day 20 of pregnancy in Cox-1KO mice compared with day-19 WT. By day 20 of pregnancy, Cox-1KO mice showed greater than fourfold increases in Ptgs2 (P = 0.01) and Ptgfr (P = 0.02) myometrial expression compared with WT mice on day 19 of pregnancy. On postpartum day 1, the transcript levels of Ptgs2 and Ptgfr remained significantly greater in Cox-1KO mice compared with time-matched WT mice (P = 0.0003 and P , 0.0001, respectively).
Given the significant differential expression of Cox-2 mRNA levels between the myometrium of WT and Cox-1KO mice on the morning of delivery, we examined whether PG levels were altered to compensate for the loss of Cox-1 in KO mice. Surprisingly, we found the PG content remained significantly lower in day-19 and day-20 uterine myometrium from Cox-1KO mice compared with WT (P , 0.05), with the exception of thromboxane B2, which was only significantly lower in day-20 pregnant Cox-1KO mice (P , 0.05). We then measured in vitro intracellular calcium release in uterine myometrial cells, using two agonists, OT and PGF 2a (Fig. 4A and 4B ), comprising two different uterotonic mechanisms of action. No difference was noted in PGF 2a -induced intracellular calcium release in uterine myometrial cells from Cox-1KO and WT mice on all days examined (P = 0.54). However, the nonlinear fourparameter curve fits of OT-induced intracellular calcium release were significantly different between uterine myometrial cells from day-20 Cox-1KO mice and day-19 Cox-1KO or WT mice (P = 0.01; Fig. 4A ). The EC 50 for OT dose response was not statistically significant between cells obtained from day-19 WT (3.193e208), day-19 Cox-1KO (9.925e209), and day-20 Cox-1KO (6.197e208) mice.
Spontaneous and agonist-induced contractions were then examined in uterine tissues from day-15 and day-19 Cox-1KO and WT mice, as well as day-20 Cox-1KO mice. Myometrial strips from gestation-matched mice of both genotypes exhibited ex vivo spontaneous contractions that were not significantly different in amplitude, frequency, or total contractile activity (AUC per defined recording period; Fig. 5A ). To determine the responsiveness of each tissue to two different uterotonins, myometrial strips were exposed to increasing concentrations of either OT (10 pM to 1 mM) or PGF 2a (10 pM to 10 mM). Day-19 and day-20 Cox-1KO uteri responded to OT with similar increases in amplitude and frequency of contraction compared with day-19 WT mice, as indicated by a single nonlinear curve that fit all data sets (P = 0.74) and similar EC 50 values (9.985e210, 1.486e209, and 1.655e209, respectively; Fig. 5B ). In contrast, myometrial contractility in response to PGF 2a exposure was significantly different between tissues from day 19 and day 20 Cox-1KO mice compared with those from day 19 WT mice. Each data set generated significantly different four-parameter nonlinear curves (P = 0.0001) without a significant difference in EC 50 values (3.788e205, 3.541e205, and 4.115e206, respectively; P = 0.93; Fig. 5C ). These results suggest that although spontaneous and OT-induced ex vivo myometrial contractility is not impaired in Cox-1KO mice, there is an altered ability to respond to PGF 2a .
Examination of in vivo uterine contractile pressure
Myometrial activity was measured in vivo to compare contractions in mice with delayed vs on-time delivery of offspring. A pressure catheter was inserted transcervically into the uterus of anesthetized mice to measure spontaneous contractile pressure before (antepartum; Fig. 6A , left panel) and during delivery (intrapartum; Fig. 6A , right panel). There was no statistical difference in intrauterine contractile pressure characteristics between antepartum Cox-1KO and WT mice, including amplitude, frequency, duration, and AUC (Fig. 6B) . Interestingly, Cox-1KO and WT mice had increased contractile force (AUC; P , 0.008) in the intrapartum period compared with antepartum, which was largely due to greater duration of contractions (P , 0.005; Fig. 6B ). These data show that uterine contractile force is unaffected in Cox-1KO mice despite the longer time needed to achieve parturition.
Efficacy of exogenous OT and P 4 withdrawal to induce on-time labor in Cox-1KO mice
Because myometrial contractility was unaltered in Cox-1KO compared with WT mice and thus should be sufficient to achieve timely delivery, we examined the ability of a potent uterotonin (i.e., OT) to rescue the delayed parturition phenotype of Cox-1KO mice and induce labor on day 19.5 of pregnancy. After subcutaneously implanting WT and Cox-1KO mice with either a saline (control) pump or an OT (uterotonic) pump on day 19 of pregnancy, we observed the timing of labor by infrared video recording. Cox-1KO mice that were continuously infused with OT at either 0.5 mU/h or 5 mU/h showed no improvement (P . 0.05) in parturition timing compared with Cox-1KO mice receiving saline control (Fig. 7A, left  panel) . Moreover, OT infusion in Cox-1KO female mice did not improve the proportion of liveborn or surviving pups compared with vehicle-treated control mice (Fig. 7A, right panel) .
Given the impaired luteolysis of Cox-1KO mice and elevated serum P 4 levels at term (29), we tested the ability of P 4 withdrawal to induce parturition in Cox-1KO mice. We used two different approaches for P 4 withdrawal: subcutaneous injection of a P 4 receptor antagonist (RU486) or ovariectomy, both of which have been shown to induce parturition in WT mice within 20 6 4 hours (26, 71, 74) . Cox-1KO mice that were injected with 0.03 mg or 0.3 mg of RU486 on day 19 of pregnancy delivered significantly earlier (P = 0.0002) than vehicle-treated Cox-1KO mice at (mean 6 SEM) 27.5 6 6.2 hours and 15.3 6 2.0 hours postinjection, respectively (Fig. 7B, left panel) . There was also a significant difference in the proportion of live/died/stillborn pups born to RU486-treated Cox-1KO mice and vehicle-treated Cox-1KO (P , 0.0001; Fig. 7B, right panel) . Similarly, Cox-1KO mice that were ovariectomized on day 19 of pregnancy delivered significantly earlier than sham-operated Cox-1KO mice (P = 0.003; Fig. 7C , left panel), at (mean 6 SEM) 29.7 6 3.4 hours vs 58.4 6 6.0 hours postinjection, and had a significant difference in the proportion of live/died/stillborn offspring per litter (P , 0.0001; Fig. 7C , right panel).
Evaluation of P 4 treatment and withdrawal on uterine and cervical function
Because P 4 withdrawal was able to significantly improve the timing of parturition in Cox-1KO female mice, we examined the ability of supplemental P 4 to induce delayed parturition and its effect on uterine and cervical function in WT mice. Endogenous serum P 4 levels remain elevated until day 18 For all gestational time points, three or more different samples from three different mice were used. (B) PG levels in the uterine myometrium were measured by gas chromatography-mass spectroscopy. At least five samples were used from different mice. Data are presented as mean 6 SEM. *P # 0.05; **P # 0.01; ***P # 0.001; ****P # 0.0001. PP1, postpartum day 1; TxB 2 , thromboxane B 2 .
of mouse pregnancy, after which they rapidly decline (62, 75) . Therefore, in the current study, pregnant WT females were treated daily with P 4 , starting on the morning of day 18 and terminating on days 19 to 21 of pregnancy. Dose-response studies showed that 2 mg/d of P 4 consistently delayed parturition (mean 6 SEM days: at 2-mg dose, 51.5% of mice delivered pups, day of delivery, 20.5 6 0.62; at 1-mg dose, 100% of mice delivered pups, day of delivery, 19.5 6 0.41).
The timing of delivery was compared in P 4 -treated and vehicle (i.e., sesame oil)-treated control WT mice. Of the mice that were able to successfully deliver offspring, control mice delivered on day 19.4 compared with P 4 -treated mice on days 18 to 19 and 18 to 20 that delivered on days 20.5 and 21.25, respectively (P , 0.0001; Fig. 8A ). Delivery outcome was significantly affected by P 4 treatment (P , 0.0001). Although vehicle-treated mice all successfully delivered offspring, only 17 mice (51.5%) treated on days 18 to 19, three mice (17.6%) treated on days 18 to 20, and no mice (0%) treated on days 18 to 21 with P 4 were able to successfully deliver offspring (Fig. 8B) .
Daily P 4 treatment did not suppress the antepartum pattern of intrauterine contractile pressures on days 19 to 21 of pregnancy compared with untreated day-19 mice ( Fig. 8C and 8D ). However, we did observe significantly increased IUPs in mice that received P 4 treatment of 72 hours compared with only 24 or 48 hours (P , 0.0001).
Together, these data show that P 4 treatment prolonged gestation in WT mice despite ongoing uterine contractions. Moreover, after 2 to 3 days of delayed parturition, successful delivery of offspring was limited despite strong intrauterine contractile pressures.
Assessment of cervical ripening
Based on results showing normal myometrial contractile function in Cox-1KO pregnant mice, as well as P 4 -treated WT pregnant mice, we addressed an alternative hypothesis that impaired cervical dilation may be a contributory factor to the Cox-1 delayed-parturition phenotype, potentially in conjunction with elevated P 4 levels. Isolated cervix tissues from day-19 Cox-1KO and WT mice, and from day-20 Cox-1KO mice were tested for their distensibility (i.e., ability to dilate). The cervix of Cox-1KO compared with those of WT mice had significantly reduced dilation under baseline conditions on day 19 of pregnancy (P = 0.005; Fig. 9A, left panel) . On day 19, the day of expected delivery, the cervices of WT mice could be stretched to 20 mm before tissue failure [total dilation; Fig. 9A, right panel] . However, in Cox-1KO mice, maximal cervical stretch was significantly reduced (P = 0.02) to only 15 mm in day-19 tissues and to 17 mm in day-20 tissues (Fig. 9A, right panel) .
We also found that P 4 treatment had no effect on the initial distensibility of the WT cervix on days 19 to 21 (Fig. 9B, left panel) compared with vehicle-treated controls. Moreover, there was no effect of P 4 treatment on total distensibility on days 19 and 20 of pregnancy. There was a significant reduction in total distensibility (P = 0.0007) in P 4 -treated mice on day 21 of pregnancy ( Fig. 9B, right panel) , as well as failure to achieve delivery of any pups (Fig. 8B) . Taken together, these data suggest that impaired cervical dilation on day 19 of pregnancy was a likely mechanism for delayed parturition in Cox-1KO mice, but this cannot be solely explained by impaired luteolysis and sustained P 4 levels, because short-term P 4 treatment failed to confer similar biomechanical characteristics in the WT cervix.
Discussion
PGs produced by two Cox isoforms are regarded as essential mediators of pregnancy and reproduction, but their contributions to the parturition process are not fully understood (76, 77) . Deletion of the Cox-2 isoform in mice disrupts fertility and the initial stages of pregnancy; Figure 5 . Spontaneous and agonist-induced ex vivo contractile activity during mid and late pregnancy in Cox-1KO and WT mice. Myometrial tissue strips (4 mm 3 12 mm) were collected from Cox-1KO and WT mice. (A) The spontaneous frequency (per 10 minutes), amplitude, and integral of contractions (AUC, normalized to the period ;600 seconds) were recorded. Increasing concentrations of (B) OT (10 pM to 1 mM) and (C) PGF 2a (10 pM to 10 mM) were added every 10 minutes, and contractile activity was analyzed for AUC per period of each concentration (B and C, right panel). Dose-response curves were analyzed using four-parameter log fit to determine whether one curve fit all the data sets using extra sum-of-squares F test. Data are presented as mean 6 SEM from two to four uterine strips from five different WT (gray diamond), day-19 Cox-1KO (open circles), and day-20 Cox-1KO (red open circles) mice. *P # 0.05; **P # 0.01; ***P # 0.001; ****P # 0.0001. M, molar concentration.
thus, it is noninformative for parturition studies. In contrast, Cox-1KO mice provide a valuable opportunity to study labor on the basis of their delayed parturition phenotype. Although mice lacking the Cox-1 gene are known to have impaired luteolysis, prior studies have not determined the mechanism or reproductive target tissue responsible for their prolonged pregnancy. The current study reveals that the timing of embryo implantation and postimplantation embryonic growth, as well as maternal reproductive tract maturation for sustained fetal development, are not impaired in Cox-1KO mice. Contrary to expectation, uterine myometrial contractile activity was completely preserved in Cox-1KO mice. Instead, we observed impaired cervical dilation in the presence of forceful uterine contractions as an underlying cause of arrested parturition. These findings are consistent with cervical dystocia and obstructed labor, similar to what is observed in women with dysfunctional parturition, and provide insights into the role of PGs in parturition.
Pregnancy establishment and the length of gestation are tightly regulated processes that safeguard fetal development and enhance survival outside the womb. Delays in blastocyst implantation, deferral of uterine receptivity, slow progression of postimplantation embryonic growth, and few progeny can prolong pregnancy beyond the optimal window for fetal development, resulting in increased neonatal morbidity and mortality (6, (78) (79) (80) . We found no evidence of a delay in implantation, decidualization, placentation, or postimplantation embryonic growth, suggesting that Cox-1KO mice have later pregnancy defects or abnormalities in antepartum mechanisms that prepare the reproductive tract for parturition.
For successful parturition to occur, the uterus must shift from a quiescent state to an active, procontractile state. As term gestation approaches, a set of well-defined CAPs are upregulated. Consistent with previous reports (81), we found higher levels of CAP genes in WT mice at term compared with day-15 pregnancy. However, in Cox-1KO mice, there was a 24-hour delay for transcript levels of Cx43, OTR, and Edn-1 to reach the levels observed in term and postpartum WT mice. Reduced uterine OT receptor (OTR) mRNA and protein expression were also reported in other mouse models of delayed or failed parturition in which mice are deficient in either Ptgfr (82), interleukin 6 (37), or Krüppel-like factor 9 (36), and in Cox-1KO mice on a mixed (C57/Bl6 3 129/ Sv) genetic background (29, 83) . Moreover, a lack of induced uterine Cx43 expression was reported in the transgene insertion on mouse chromosome 6 (Tg/Tg) mouse model of delayed parturition (84) . Interestingly, Ptgs2 and Ptgfr transcripts reached higher levels on day 20 and in postpartum Cox-1KO mice compared with term day-19 and postpartum WT mice, suggesting compensatory upregulation to accomplish parturition. However, when we examined PG content in day-19 pregnant Cox-1KO mice, we found very low uterine PG levels. Although it is well-known that uterine Ptgs2 is induced during active labor (46, 74, 81) and on postpartum day 1, there is disagreement over whether Cox-2-derived PGs contribute to the final pathway of parturition (46, 85) or if Cox-2 expression is the result of labor progression rather than its initiation (35, 81) . Given the low levels of PG in Cox-1KO uterine myometrium on the day of labor, it appears that PGs are not necessary for the initiation of labor in these mutant mice. Steroid hormones (74, 81, 86) , proinflammatory cytokines, and mechanical stretch signals during late pregnancy (87, 88) are known to affect the expression of CAPs, including Cx43, OTR, and Ptgs2. Thus, it remains to be determined whether the delay in expression of these CAPs in the Cox-1KO uterus was due to abnormal P 4 levels, increased uterine stretch from postdate embryos, or alterations in proinflammatory mediators. However, regardless of the underlying mechanism for delayed CAP expression in the myometrium of Cox-1KO pregnant mice, the uterine contractility of these mice was unaltered.
The expression of CAPs primes the uterus for contraction before the release of uterotonins such as OT and PGF 2a during labor. Despite the low levels of Cx43, OTR, and Ptgfr in Cox-1KO mouse uteri on the expected day of delivery, we observed no differences between WT and Cox-1KO mice in (1) OT-induced intracellular calcium release, (2) spontaneous and OT-induced ex vivo uterine contractility, or (3) in vivo contractile pressure. However, other mouse models of delayed parturition reported either unaltered (30, 82) , delayed (84), or impaired (67) uterine contractile phenotypes. To our knowledge, uterine contractile activity has yet to be reported in other models of delayed parturition, including mice with mutations in cytosolic phospholipase A 2 (cPLA2) (6, 27) ; Cx43 (34); 20a-hydroxysteroid dehydrogenase (32); interleukin-6 (37); KLF-9 (36); lysophosphatidic acid (33) ; mastermind like domain containing 1 (41); steroid receptor coactivators 1 and 2 (40); sushi-ichi retrotransposon homolog 7/leucine zipper, downregulated in cancer 1 (39); cytochrome P450, family11, subfamily A, polypeptide1 transgenic mice (38) ; and mice with an overexpression of the mouse estrogen receptor (24) . The absence of information on myometrial contractility in these models prevents appropriate elucidation of the delayed parturition phenotype beyond their reported endocrine or cervical deficiencies. P 4 is considered the maintenance hormone of pregnancy in most species, because of high circulating levels of P 4 or a balance of PR-A and PR-B P 4 receptor signaling, coactivator expression, steroid metabolism, and other mechanisms that favor uterine quiescence (12) (13) (14) (15) (16) (17) . In species that undergo P 4 withdrawal, ovariectomy or treatment with P 4 -receptor antagonists results in increased OTR expression, uterine contractility, cervical ripening, and delivery of offspring. P 4 withdrawal has been shown to restore the normal timing of parturition in mice deficient in PGF 2a receptor (67) , SRD5aR1 (30) , and 20a-hydroxysteroid dehydrogenase (32) . However, the parturition defect persisted in our Cox-1KO mice, which is similar to the Krüppel-like factor 9 (36) mutated mouse model of delayed parturition and the Tg/Tg (84) mouse model of failed parturition. Previous studies demonstrated impaired luteolysis and abnormally sustained P 4 levels in Cox-1KO mice on the 129/Bl6 strain (29, 83) . Although ovariectomy or treatment with a P 4 receptor antagonist did significantly improve the timing of parturition in our Cox-1KO mice, only treatment with RU486 resulted in the onset of parturition within 24 hours, similar to previous reports using WT mice (26, 71, 74) . Therefore, it appears that impaired P 4 withdrawal is not the sole mechanism for delayed parturition in Cox-1KO mice. To address this, we performed a reciprocal experiment showing that excess P 4 significantly delayed the parturition timing of WT mice, consistent with previous reports (60) (61) (62) . Surprisingly, delayed parturition in Cox-1KO mice and in P 4 -treated WT mice was not caused by a reduction in uterine contractions. This study reports in vivo data showing that intrauterine contractile pressures are normal in Cox-1KO mice with delayed parturition, and that P 4 supplementation prolongs gestation in WT mice despite ongoing myometrial contractions.
Successful parturition depends on a concerted effort between rhythmic uterine contractions and progressive dilation of the cervix. Forceful uterine contractions in the absence of a soft, ripened cervix has been reported in two prior mouse models of delayed parturition: SRD5aR1 null mice (30) and Tg/Tg transgene insertion mice (84) . In each of these models, a rigid cervix was noted, accompanied by impaired cervical dilation. However, the cervical phenotype of Tg/Tg mice is distinct from SRD5aR1 mice due to the many inflammatory cells, differential induction of inflammatory response genes, and failure of antiprogestin treatment or ovariectomy to rescue the delayed parturition phenotype (84) . It remains to be determined whether the cervical phenotype of Cox-1KO mice is distinct or favors that observed in SRD5aR1 (30) or Tg/Tg (84) mice. The Cox-1KO cervix had significantly reduced dilation under resting and peak load conditions on the morning of expected delivery. Although this was a surprising finding given the low levels of Cox-1 expression and PG synthesis in the WT cervix during most of pregnancy (89, 90) , high levels of Cox-1 expression in the nearby uterine luminal epithelium may provide the source of PGs needed for normal cervical maturation (90) . Alternatively, impaired cervical distensibility in Cox-1KO mice may be the result of elevated P 4 levels; however, P 4 treatment only affected the distensibility of the WT cervix after prolonged exposure. Thus, it appears that the impaired cervical dilation in Cox-1KO mice is due to both the lack of Cox-1 and prolonged elevation of P 4 levels.
Humans with platelets deficient in Cox-1 activity have been identified (91) , as have genetic polymorphisms in human Cox-1 (92) . However, to our knowledge, there are no reports that have investigated possible parturition difficulties in women with Cox-1 deficiency or polymorphisms. The uterus of Cox-1KO and cPLA2-deficient mice have reduced PG content (6, 31) , but their myometrial activity was heretofore unknown. Deletion of cPLA2, the critical upstream enzyme for PG synthesis, results in delayed embryo implantation and abnormal embryo spacing, causing a downstream "ripple effect" (4), which delays parturition but preserves the normal gestational period for fetal growth by deferring the timing of birth (6) . In comparison, Cox-1KO mice represent a truly prolonged pregnancy, with ongoing fetal growth and regression of the postmature placenta despite ongoing labor. Mice lacking Ptgfr share a similar phenotype, with intact contractions despite deletion of a critical PG pathway (82) . Our studies extend these observations to show that products of Cox-1 have more effect on cervical distensibility than their anticipated contractile contributions to parturition. Moreover, we recently found a delay in cervical hydration and collagen content in Cox-1KO mice that corresponds to the delay in cervical dilation, suggesting a possible mechanism for their parturition phenotype (90) . Consistent with studies in human tissues, Cox-1 is expressed in the human uterus and produces PGs that are speculated to bind to receptors in the cervix to allow cervical ripening and dilatation for labor, as well as facilitating effective propagation of contractions from the fundus to cervix (93, 94) . Overall, these features mimic women with postdates, prolonged pregnancy (longer than 41 to 42 weeks' gestation), which occurs in ;5% to 10% of all pregnancies worldwide (78, 79) .
Collectively, this study demonstrates that delayed parturition in Cox-1KO mice could not be attributed to impaired embryo implantation, fetal maturation, or abnormal uterine contractility. Alternatively, we identified impaired cervical distensibility as a barrier to delivery that could not be overcome by normal uterine contractions or exogenous OT supplementation, and a likely cause for delayed parturition. This investigation offers insights into the role of Cox-1-derived prostaglandins during pregnancy and parturition, and shows that Cox-1KO mice are a useful resource to study cervical dystocia and obstructed labor, conditions that are mechanistically difficult to study in women.
